Pablo Guisado Vasco

🧵 Los Hantavirus: Análisis del brote actual y claves científicas 1/3 Situación actual 🚢 Las autoridades monitorean un cluster de casos con clínica respiratoria aguda grave en un crucero de bandera neerlandesa en el Atlántico. A fecha de 4 de mayo de 2026, el buque se encuentra frente a la costa de Cabo Verde 🇨🇻 con 149 personas a bordo. Cifras del brote 📊 Se han identificado 7 casos en total: 2 confirmados por laboratorio y 5 sospechosos. El balance incluye 3 fallecimientos, 1 paciente en estado crítico y 3 personas con síntomas leves. Evolución clínica 🌡️ El inicio de los síntomas ocurrió entre el 6 y el 28 de abril de 2026. El cuadro se caracteriza por fiebre y síntomas gastrointestinales, con una progresión rápida a neumonía, síndrome de dificultad respiratoria aguda (SDRA) y shock.

📣Take-home message: In these large UK (PANORAMIC) and Canadian (CanTreatCOVID) randomized trials, early Paxlovid treatment in vaccinated, higher-risk community patients failed to reduce an already-low rate of hospitalization or death. End #IDTwitter #COVID19

🔙 Let's go back to EPIC-HR (2021) ➡️ Unvaccinated patients: 89% relative risk reduction. ❓ Why the difference now? 🛡️ Vaccination (+ serostatus) has slashed baseline risk. Little room is left for the drug to act. 3/4

At last published @NEJM ➡️ Paxlovid tested in 4,232 vaccinated, high-risk COVID outpatients. 📊 Result: NO reduction in hospitalization or death. ⚠️ Event rates were tiny in both arms (~0.7–1.2%). The pre-vaccine-era benefit is gone (no surprise). 🧵1/4 nejm.org/doi/full/10.10…

I wrote this in a moment I never would have chosen. A sudden pause that made me see my life clearly. The meaning of our work is profound. This experience simply helped me see more clearly what matters most. “Time is Finite” JAMA jamanetwork.com/journals/jama/…

Our new preprint by @peowenlu @SaefIzzy @weinerlabhms and colleagues shows that nasal anti-CD3 monoclonal antibody treatment can reduce neuroinflammation in a mouse model of Long COVID, even when administered at 4 weeks after infection 🧠 biorxiv.org/content/10.648…

Earthset. The Artemis II crew captured this view of an Earthset on April 6, 2026, as they flew around the Moon. The image is reminiscent of the iconic Earthrise image taken by astronaut Bill Anders 58 years earlier as the Apollo 8 crew flew around the Moon.

PD: Before any steady negative conclusion, I prefer to read the full paper when published. At the moment, the ACC26 abstract is under embargo The design of the study is here: #study-plan" target="_blank" rel="nofollow noopener">clinicaltrials.gov/study/NCT06305…

5/5 | Key takeaway: in Long COVID POTS, slowing the heart rate isn't enough on its own (we know it 😉). Ivabradine may still have a role, but only as part of a structured, multidisciplinary approach. Subgroup analyses (e.g., norepinephrine phenotypes) ongoing. #LongCovid #ACC26

1/5 🧵 BREAKING from #ACC26 | RECOVER-AUTONOMIC trial results are in: Ivabradine vs placebo in Long COVID POTS The largest RCT ever in Long COVID POTS. Here's what we know for the moment👇

1) Had a look at Putrino's trial on "Microtesla Magnetic Therapy" for Long Covid. Unfortunately, I don't think the trial shows effectiveness. They used 44 outcomes that weren't pre-registered or corrected for multiple comparisons so differences might simply be due to chance.

Here is the link: science.org/doi/10.1126/sc…

New in @ScienceMagazine: Researchers have identified a specific neural pathway (Pdyn+ sympathetic neurons) that orchestrates the "stress-to-dermatitis" flare-up 🧠➡️⚡️➡️🧴 Incredible proof of how extensively the autonomic nervous system is wired into our immune responses.

👇👇

How specific are therapeutic monoclonal antibodies, really? In our new paper, @Yile_Dai led a collaboration with Adimab to profile 174 FDA-approved and clinical-stage mAbs against 6,172 human extracellular proteins. What we found surprised us.🧵 sciencedirect.com/science/articl…